Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit

Journal of Immunology

Volumn 170, Issue 1, 2003, Pages 454-462

  Boyaka, Prosper N ^a   Ohmura, Mari ^a,b   Fujihashi, Kohtaro ^a   Koga, Toshiya ^a   Yamamoto, Masafumi ^b,d   Kweon, Mi Na ^b   Takeda, Yoshifumi ^e   Jackson, Raymond J ^a   Kiyono, Hiroshi ^a,b,c   Yuki, Yoshikazu ^c   McGhee, Jerry R ^a  

^a University of Alabama at Birmingham   (United States)

^b OSAKA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NIHON UNIVERSITY   (Japan)

^e JISSEN WOMEN'S UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; CD4 ANTIGEN; CHOLERA TOXIN; ENTEROTOXIN; GAMMA INTERFERON; HEAT LABILE TOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 4; OVALBUMIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESCHERICHIA COLI; HELPER CELL; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; UPREGULATION;

EID: 0037218655     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.1.454     Document Type: Article

References (65)

1. Spangler, B. D. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622.
2. Rappuoli, R., M. Pizza, G. Douce, and G. Dougan. 1999. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today 20:493.
3. Angstrom, J., M. Backstrom, A. Berntsson, N. Karlsson, J. Holmgren, K. A. Karlsson, M. Lebens, and S. Teneberg. 2000. Novel carbohydrate binding site recognizing blood group A and B determinants in a hybrid of cholera toxin and Escherichia coli heat-labile enterotoxin B-subunits. J. Biol. Chem. 275:3231.
4. Galvan, E. M., G. A. Roth, and C. G. Monferran. 1999. Participation of ABH glycoconjugates in the secretory response to Escherichia coli heat-labile toxin in rabbit intestine. J. Infect. Dis. 180:419.
5. Karlsson, K. A., S. Teneberg, J. Angstrom, A. Kjellberg, T. R. Hirst, J. Berstrom, and H. Miller-Podraza. 1996. Unexpected carbohydrate cross-binding by Escherichia coli heat-labile enterotoxin: Recognition of human and rabbit target cell glycoconjugates in comparison with cholera toxin. Bioorg. Med. Chem. 4:1919.
6. Fukuta, S., J. L. Magnani, E. M. Twiddy, R. K. Holmes, and V. Ginsburg. 1988. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect. Immun. 56:1748.
7. Field, M., M. C. Rao, and E. B. Chang. 1989. Intestinal electrolyte transport and diarrheal disease (1). N. Engl. J. Med. 321:800.
8. Elson, C. O., and W. Ealding. 1984. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J. Immunol. 133:2892.
9. Clements, J. D., N. M. Hartzog, and F. L. Lyon. 1988. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6:269.
10. Lycke, N., and J. Holmgren. 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59:301.
11. Yamamoto, S., Y. Takeda, M. Yamamoto, H. Kurazono, K. Imaoka, M. Yamamoto, K. Fujihashi, M. Noda, H. Kiyono, and J. R. McGhee. 1997. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185:1203.
12. Yamamoto, S., H. Kiyono, M. Yamamoto, K. Imaoka, K. Fujihashi, F. W. van Ginkel, M. Noda, Y. Takeda, and J. R. McGhee. 1997. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA 94:5267.
13. Douce, G., M. Fontana, M. Pizza, R. Rappuoli, and G. Dougan. 1997. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65:2821.
14. Douce, G., C. Turcotte, I. Cropley, M. Roberts, M. Pizza, M. Domenghini, R. Rappuoli, and G. Dougan. 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 92:1644.
15. de Haan, L., W. R. Verweij, I. K. Feil, T. H. Lijnema, W. G. Hol, E. Agsteribbe, and J. Wilschut. 1996. Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin. Infect. Immun. 64:5413.
16. Giuliani, M. M., G. Del Giudice, V. Giannelli, G. Dougan, G. Douce, R. Rappuoli, and M. Pizza. 1998. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187:1123.
17. Douce, G., V. Giannelli, M. Pizza, D. Lewis, P. Everest, R. Rappuoli, and G. Dougan. 1999. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect. Immun. 67:4400.
18. Foss, D. L., M. J. Zilliox, and M. P. Murtaugh. 1999. Differential regulation of macrophage interleukin-1 (IL-1), IL-12, and CD80-CD86 by two bacterial toxins. Infect. Immun. 67:5275.
19. Gagliardi, M. C., F. Sallusto, M. Marinaro, A. Langenkamp, A. Lanzavecchia, and M. T. De Magistris. 2000. Cholera toxin induces maturation of human dendritic cells and licenses them for Th2 priming. Eur. J. Immunol. 30:2394.
20. Yamamoto, M., H. Kiyono, M.-N. Kweon, S. Yamamoto, K. Fujihashi, H. Kurazono, K, Imaoka, H. Bluethmann, I. Takahashi, Y. Takeda, et al. 2000. Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses, J. Infect. Dis. 182:180.
21. Yamamoto, M., H. Kiyono, S. Yamamoto, E. Batanero, M. N. Kweon, S. Otake, M. Azuma, Y. Takeda, and J. R. McGhee. 1999. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J. Immunol. 162:7015.
22. Hirai, T., S. Hashiguchi, N, Torigoe, Y. Toda, Y. Ito, and K. Sugimura. 2000. Intranasal sensitization of Japanese cedar pollen by the co-administration of low doses of cholera toxin but not its recombinant B subunit to mice. Microbiol. Immunol. 44:259.
23. Rask, C., M. Fredriksson, M. Lindblad, C. Czerkinsky, and J. Holmgren. 2000. Mucosal and systemic antibody responses after peroral or intranasal immunization: Effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant. APMIS 108:178.
24. de Haan, L., I. K. Feil, W. R. Verweij, M. Holtrop, W. G. Hol, E. Agsteribbe, and J. Wilschut. 1998. Mutational analysis of the role of ADP-ribosylation activity and GMI-binding activity in the adjuvant properties of the Escherichia coli heatlabile enterotoxin towards intranasally administered keyhole limpet hemocyanin. Eur. J. Immunol. 28:1243.
25. Marinaro, M., H. F. Staats, T. Hiroi, R. J. Jackson, M. Coste, P. N. Boyaka, N. Okahashi, M. Yamamoto, H. Kiyono, H. Bluethmann, et al. 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:4621.
26. Marinaro, M., P. N. Boyaka, R. J. Jackson, F. D. Finkelman, H. Kiyono, E. Jirillo, and J.R. McGhee. 1999. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J. Immunol. 162:114.
27. Vajdy, M., M. H. Kosco-Vilbois, M. Kopf, G. Kohler, and N. Lycke. 1995. Impaired mucosal immune responses in interleukin 4-targeted mice. J. Exp. Med. 181:41.
28. + Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infect. Immun. 64:1516.
29. Braun, M. C., J. He, C. Y. Wu, and B. L. Kelsall. 1999. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor β1 and β2 chain expression. J. Exp. Med. 189:541.
30. Takahashi, I., M. Marinaro, H. Kiyono, R. J. Jackson, I. Nakagawa, K. Fujihashi, S. Hamada, J. D. Clements, K. L. Bost, and J. R. McGhee. 1996. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173:627.
31. Finkelman, F. D., J. Holmes, I. M. Katona, J. F. Urban, Jr., M. P. Beckmann, L. S. Park, K. A. Schooley, R. L. Coffman, T. R. Mosmann, and W. E. Paul. 1990. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8:303.
32. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties Annu. Rev. Immunol. 7:145.
33. Porgador, A., H. F. Staats, B. Faiola, E. Gilboa, and T. J. Palker, 1997. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J. Immunol. 158:834.
34. Neidleman, J. A., M. Vajdy, M. Ugozzoli, G. Ott, and D. O'Hagan. 2000. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55. Immunology 101:154.
35. Belyakov, I. M., J. D. Ahlers, J. D. Clements, W. Strober, and J. A. Berzofsky. 2000. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. J. Immunol. 165:6454.
36. Simmons, C. P., P. Mastroeni, R. Fowler, M. Ghaem-Maghami, N. Lycke, M. Pizza, R. Rappuoli, and G. Dougan. 1999. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J. Immunol. 163:6502.
37. Bowman, C. C., and J. D. Clements. 2001. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids. Infect. Immun. 69:1528.
38. Ryan, E. J., E. McNeela, G. A. Murphy, H. Stewart, D. O'Hagan, M. Pizza, R. Rappuoli, and K. H. Mills. 1999. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 67:6270.
39. Goto, N., J. Maeyama, Y. Yasuda, M. Isaka, K. Matano, S. Kozuka, T. Taniguchi, Y. Miura, K. Ohkuma, and K. Tochikubo. 2000. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Vaccine 18:2164.
40. Clements, J. D., D. C. Flint, R. F. Engert, and F. A. Klipstein. 1983. Cloning and molecular characterization of the B subunit of Escherichia coli heat-labile enterotoxin, Infect. Immun. 40:653.
41. Ito, H., T. Yutsudo, T. Hirayama, and Y. Takeda. 1988. Isolation and some properties of A and B subunits of Vero toxin 2 and in vitro formation of hybrid toxins between subunits of Vero toxin I and Vero toxin 2 from Escherichia coli 0157:H7. Microb. Pathog. 5:189.
42. Kweon, M.-N., M. Yamamoto, F. Watanabe, S. Tamura, F. W. van Ginkel, A. Miyauchi, H. Takagi, Y. Takeda, T. Hamabata, K. Fujihashi, et al. 2002. A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE Ab. J. Infect. Dis. 186:1261.
43. Yamamoto, M., D. E. Briles, S. Yamamoto, M. Ohmura, H. Kiyono, and J. R. McGhee. 1998. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J. Immunol. 161:4115.
44. Lillard, J. W., Jr., P. N. Boyaka, J. A. Hedrick, A. Zlotnik, and J. R. McGhee. 1999. Lymphotactin acts as an innate mucosal adjuvant. J. Immunol. 162:1959.
45. Marinaro, M., P. N. Boyaka, F. D. Finkelman, H. Kiyono, R. J. Jackson, E. Jirillo, and J. R. McGhee. 1997. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J. Exp. Med. 185:415.
46. Jackson, R.J., K. Fujihashi, H. Kiyono, and J. R. McGhee. 1996. Luminometry: A novel bioluminescent immunoassay enhances the quantitation of mucosal and systemic antibody responses. J. Immunol. Methods 190:189.
47. Jackson, R. J., K. Fujihashi, J. Xu-Amano, H. Kiyono, C. O. Elson, and J. R. McGhee. 1993. Optimizing oral vaccines: Induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect. Immun. 61:4272.
48. VanCott, J. L., H. F. Staats, D. W. Pascual, M. Roberts, S. N. Chatfield, M. Yamamoto, M. Coste, P. B. Carter, H. Kiyono, and J. R. McGhee. 1996. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. J. Immunol. 156:1504.
49. Rodighiero, C., A. T. Aman, M. J. Kenny, J. Moss, W. I. Lencer, and T. R. Hirst. 1999. Structural basis for the differential toxicity of cholera toxin and Escherichia coli heat-labile enterotoxin: Construction of hybrid toxins identifies the A2-domain as the determinant of differential toxicity. J. Biol. Chem. 274:3962.
50. Barchfeld, G. L., A. L. Hessler, M. Chen, M. Pizza, R. Rappuoli, and G. A. Van Nest. 1999. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine 17:695.
51. Ghiara, P., M. Rossi, M. Marchetti, A. Di Tommaso, C. Vindigni, F. Ciampolini, A. Covacci, J. L. Telford, M. T. De Magistris, M. Pizza, et al. 1997. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect. Immun. 65:4996.
52. Nashar, T.O., H. M. Webb, S. Eaglestone, N.A. Williams, and T.R. Hirst. 1996. Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: Receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc. Natl. Acad. Sci. USA 93:226.
53. Holmgren, J., P. Fredman, M. Lindblad, A. M. Svennerholm, and L. Svennerholm. 1982. Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin. Infect. Immun. 38:424.
54. Holmgren, J., M. Lindblad, P. Fredman, L. Svennerholm, and H. Myrvold. 1985. Comparison of receptors for cholera and Escherichia coli enterotoxins in human intestine. Gastroenterology 89:27.
55. Xu-Amano, J., H. Kiyono, R. J. Jackson, H. F. Staats, K. Fujihashi, P. D. Burrows, C. O. Elson, S. Pillai, and J. R. McGhee. 1993. Helper T cell subsets for immunoglobulin A responses: Oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J. Exp. Med. 178:1309.
56. Peterson, J. W., R. A. Finkelstein, J. Cantu, D. L. Gessell, and A. K. Chopra. 1999. Cholera toxin B subunit activates arachidonic acid metabolism. Infect. Immun. 67:794.
57. 2 promotes IL-4-induced IgE and IgGI synthesis. J. Immunol. 145:2644.
58. 2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 150:5321.
59. + T cells. Mol. Immunol. 35:39.
60. 2 primes naive T cells for the production of antiinflammatory cytokines. Eur. J. Immunol. 27:3526.
61. Hotomi, M., N. Yamanaka, J. Shimada, M. Suzumoto, Y. Ikeda, A. Sakai, J. Arai, and B. Green. 2002. Intranasal immunization with recombinant outer membrane protein P6 induces specific immune responses against nontypeable Haemophilus influenzae. Int. J. Pediatr. Otorhinolaryngol. 65:109.
62. Kurono, Y., M. Yamamoto, K. Fujihashi, S. Kodama, M. Suzuki, G. Mogi, J.R. McGhee, and H. Kiyono. 1999. Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity. J. Infect. Dis. 180:122.
63. Snapper, C. M., and W. E. Paul. 1987. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236:944.
64. + T cells. Annu. Rev. Immunol. 12:635.
65. Williams, N. A., T. R. Hirst, and T. O. Nashar. 1999. Immune modulation by the cholera-like enterotoxins: From adjuvant to therapeutic. Immunol. Today 20:95.